Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the diseaseGeorg Jeryczynski, Heinz Gisslinger, Jürgen Thiele et al.|American Journal of Hematology|2017Cited by 66
Intensive consolidation with G‐CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 yearsWolfgang R. Sperr, Peter Valent, Ansgar Weltermann et al.|American Journal of Hematology|2017Cited by 11
Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statementThamer Sliwa, Heinz Gisslinger, Christine Beham‐Schmid et al.|Wiener klinische Wochenschrift|2016Cited by 9
Ruxolitinib therapy for myelofibrosis in AustriaMaria‐Theresa Krauth, Heinz Gisslinger, Sonja Burgstaller et al.|Wiener klinische Wochenschrift|2018Cited by 6
Austrian recommendations for the management of polycythemia veraSonja Burgstaller, Heinz Gisslinger, Veronika Buxhofer‐Ausch et al.|Wiener klinische Wochenschrift|2018Cited by 4